Virtual Library

Start Your Search

Houda El Benna



Author of

  • +

    EP1.01 - Advanced NSCLC (ID 150)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.01-58 - Impact of Tumour Size on the Management and Outcome of Stage III Non-Small Cell Lung Cancer (NSCLC) (Now Available) (ID 1940)

      08:00 - 18:00  |  Author(s): Houda El Benna

      • Abstract
      • Slides

      Background

      We aimed to evaluate the difference in clinical/radiological presentation and patient management according to tumour size in stage III NSCLC. We also reported its impact on patient’s outcome.

      Method

      We retrospectively studied 88 patients with stage III NSCLC treated between 2010 and mid-2017 in our oncology department. Various cut-off values for tumour diameter were evaluated. We selected a cut-off value of 4 cm, and considered two groups: tumour size≤4 cm and >4 cm. Epidemiological, anatomo-clinical parameters were collected and compared. Kaplan-Meier method was used to evaluate survival.

      Result

      Differences in characteristics of the two groups were described in table 1.

      Initial therapeutic strategy was significantly correlated with tumour size; in tumour≤4 cm therapy was concurrent chemoradiation in 0%, neoadjuvant chemotherapy in 53%, upfront surgery 47% vs 25%, 61%, and 14% respectively for tumour size>4 cm group (p=0.003).

      Among patients receiving neoadjuvant chemotherapy, response was not correlated to tumour size; in≤4 cm group we observed (Partial response (PR) 89%, stable disease (SD)11%, Progressive disease(PD) 0%), in >4cm group response was (PR 39%, SD 36%, PD 25%)(p=0.6). Surgery (upfront or after neoadjuvant chemotherapy) was significantly higher in tumour ≤4cm (65% vs 20%) (p=0.0001). Definitive chemoradiation was more indicated in larger tumours, without statistical significance (75% vs 46%)(p=0.4). Therapeutic discordance between the planned and the administered treatment was significantly higher in larger tumours (68% vs 18%) (p=0.0001). Progression free survival was longer in smaller tumours (18±9.3 vs 11±12.1 months) without being statistically significant. However, median overall survival was significantly correlated with tumour size (41.7± 5.1 in ≤4 cm, 32.8±4.6 months in > 4 cm) (p=0.04). The pattern of recurrence was not correlated to tumour size; it was locoregional in 30%, distant in 20% and both locoregional/distant in 50% in≤4 cm group vs 42%, 24%, and 34% respectively in tumour size> 4 cm (p=0.6).

      Table 1: Characteristics of patients in the two preselected groups.

      Patient characteristics

      Tumour size ≤4 cm

      (n=17)

      Tumour size> 4 cm

      (n=71)

      P

      Age at diagnosis

      Median ± SD (years)

      Elderly (≥70 years),%

      Young (<70 years),%

      .

      59±9.1

      6%

      94%

      .

      62.27±10.8

      28%

      72%

      0.25

      0.05

      Gender, %

      Male

      Female

      .

      59%

      41%

      .

      87%

      13%

      0.006

      Performance Status, %

      0

      1

      2

      .

      6%

      94%

      0%

      .

      1%

      83%

      16%

      0.02

      Weight loss, %

      18%

      42%

      0.06

      Histological type, %

      Adenocarcinoma

      Squamous cell carcinoma

      large cell carcinoma

      .

      88%

      12%

      0%

      .

      47%

      52%

      1%

      0.008

      Histological grade, %

      Well differentiated

      Moderately differentiated

      Poorly differentiated

      .

      18%

      76%

      6%

      .

      24%

      48%

      28%

      0.075

      T Status, %

      T1

      T2

      T3

      T4

      .

      24%

      29%

      29%

      18%

      .

      0%

      7%

      18%

      75%

      0.0001

      N Status,%

      N0

      N1

      N2

      N3

      .

      6%

      6%

      71%

      17%

      .

      10%

      15%

      58%

      17%

      0.67

      Stage,%

      IIIA

      IIIB

      .

      77%

      23%

      .

      44%

      56%

      0.015

      Conclusion

      When taking 4 cm as a cut-off value, tumour size influenced clinical presentation and management modalities. It may be considered as a prognostic factor in stage III NSCLC.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.